Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Automated estimated GFR reporting: A new tool to promote safer prescribing in patients with chronic kidney disease?

Authors KPG Harris, Bernie Stribling

Published 15 November 2007 Volume 2007:3(5) Pages 969—972

KPG Harris1, Bernie Stribling2

1University Hospitals of Leicester NHS Trust; 2East Midlands Renal Network

Abstract: A number of drugs rely on the kidney for excretion and thus require their dose to be modified in any patients where there is renal impairment. Others are nephrotoxic and should be avoided completely in patients with renal disease. Traditionally clinicians have had to rely on serum creatinine to assess renal function but this may not accurately reflect the kidney function of an individual since its level also depends on muscle mass. In particular elderly females may have significant impairment of renal function despite a normal or near normal serum creatinine. The advent of automated reporting of estimated glomerular filtration rate (eGFR) provides the clinician with simple, easily understood and readily available measurement which more accurately reflects a patient’s renal function. In particular eGFR allows the clinician to readily identify and stratify patients with chronic kidney disease (CKD) and can allow a more rational and safer approach to prescribing in this group of high risk patients. This commentary suggests that national prescribing formularies should use eGFR to provide consistent advice about the appropriate dose adjustment and avoidance of potentially toxic drugs at various stages of CKD. Such an approach may prove invaluable in improving prescribing in CKD and avoiding drug toxicity in this group of patients.

Keywords: eGFR, chronic kidney disease, prescribing

Download Article [PDF] 

Readers of this article also read:

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis

José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-Centeno

Therapeutics and Clinical Risk Management 2008, 4:1305-1313

Published Date: 5 December 2008

Posaconazole in the management of refractory invasive fungal infections

Stefan Langner, Philipp B Staber, Peter Neumeister

Therapeutics and Clinical Risk Management 2008, 4:747-757

Published Date: 8 August 2008

Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology

Sapna Modi, Livia Van, Aron Gewirtzman, Natalia Mendoza, Brenda Bartlett, et al

Therapeutics and Clinical Risk Management 2008, 4:409-417

Published Date: 11 April 2008

Optimizing medicines management: From compliance to concordance

Annie Cushing, Richard Metcalfe

Therapeutics and Clinical Risk Management 2007, 3:1047-1058

Published Date: 15 January 2008

Effectiveness of lifestyle measures in the treatment of gastroesophageal reflux disease – a case series

Madeleine Nowak, Petra Büttner, Simone Harrison, Kym Daniell, Beverly Raasch, Rick Speare

Therapeutics and Clinical Risk Management 2006, 2:329-334

Published Date: 15 September 2006